These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11352187)

  • 21. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
    Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
    Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linkage analysis of candidate loci for end-stage renal disease due to diabetic nephropathy.
    Iyengar SK; Fox KA; Schachere M; Manzoor F; Slaughter ME; Covic AM; Orloff SM; Hayden PS; Olson JM; Schelling JR; Sedor JR
    J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S195-201. PubMed ID: 12819328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing patterns of end-stage renal disease due to hypertension.
    Qualheim RE; Rostand SG; Kirk KA; Rutsky EA; Luke RG
    Am J Kidney Dis; 1991 Sep; 18(3):336-43. PubMed ID: 1882825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus.
    Freedman BI; Tuttle AB; Spray BJ
    Am J Kidney Dis; 1995 May; 25(5):710-3. PubMed ID: 7747724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
    Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
    JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BP and Renal Outcomes in Diabetic Kidney Disease: The Veterans Affairs Nephropathy in Diabetes Trial.
    Leehey DJ; Zhang JH; Emanuele NV; Whaley-Connell A; Palevsky PM; Reilly RF; Guarino P; Fried LF;
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2159-69. PubMed ID: 26482258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of progression of diabetic nephropathy: implication for timing of kidney transplantation.
    Cheng SS; Wilson DM; Munn SR
    Clin Transplant; 1997 Aug; 11(4):334-6. PubMed ID: 9267725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors affecting the progression of diabetic nephropathy and its complications: a single-center experience in Saudi Arabia.
    Alwakeel JS; Isnani AC; Alsuwaida A; Alharbi A; Shaffi SA; Almohaya S; Al Ghonaim M
    Ann Saudi Med; 2011; 31(3):236-42. PubMed ID: 21623051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy.
    Fernández-Juárez G; Villacorta Perez J; Luño Fernández JL; Martinez-Martinez E; Cachofeiro V; Barrio Lucia V; Tato Ribera AM; Mendez Abreu A; Cordon A; Oliva Dominguez JA; Praga Terente M
    Nephrology (Carlton); 2017 May; 22(5):354-360. PubMed ID: 27003829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
    Freedman BI; Wuerth JP; Cartwright K; Bain RP; Dippe S; Hershon K; Mooradian AD; Spinowitz BS
    Control Clin Trials; 1999 Oct; 20(5):493-510. PubMed ID: 10503809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria.
    Zitt E; Pscheidt C; Concin H; Kramar R; Lhotta K; Nagel G
    PLoS One; 2016; 11(8):e0161376. PubMed ID: 27537361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for a composite end-point of renal outcomes in patients with chronic kidney disease.
    Morita S; Fukuhara S; Akizawa T; Asano Y; Koshikawa S; Koide K; Kurokawa K
    Ther Apher Dial; 2006 Feb; 10(1):72-7. PubMed ID: 16556140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients.
    Steinke JM; Mauer M;
    Pediatr Endocrinol Rev; 2008 Aug; 5 Suppl 4():958-63. PubMed ID: 18806710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease in lebanese patients with diabetic nephropathy.
    Fawwaz S; Balbaa M; Fakhoury H; Borjac J; Fakhoury R
    Saudi J Kidney Dis Transpl; 2017; 28(2):325-329. PubMed ID: 28352015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans.
    Bakris GL; Mangrum A; Copley JB; Vicknair N; Sadler R
    Hypertension; 1997 Mar; 29(3):744-50. PubMed ID: 9052890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
    Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
    Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Racial factors in the incidence and causation of end-stage renal disease (ESRD).
    Easterling RE
    Trans Am Soc Artif Intern Organs; 1977; 23():28-33. PubMed ID: 910346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Racial differences in the incidence of end-stage renal disease.
    Tell GS; Hylander B; Craven TE; Burkart J
    Ethn Health; 1996 Mar; 1(1):21-31. PubMed ID: 9395545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.